News >

FDA Approval Sought for Darolutamide for Nonmetastatic CRPC

OncLive Staff
Published: Wednesday, Feb 27, 2019

A new drug application (NDA) has been filed with the FDA for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to the codevelopers of the investigational agent, Bayer and Orion Corporation.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x